LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...
AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...
Investor's Business Daily on MSN1h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback